Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aiviva, Alnylam, Alpine, Anixa, Apnimed, Atyr, Bridgebio, Candel, Corium, Hanall, Hepion, Immix, Medincell, Milestone, Mink, Mirum, Neurimmune, Novartis, Novo Nordisk, Rain, Redhill, Regeneron, Salubris, Vicore.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alligator, Antengene, Galera, Immupharma, Pepgen, Vifor, Westvac.

China's National Medical Products Administration (NMPA) has given drug clinical trial approval for two new COVID-19 vaccines against the current XBB variants developed by Westvac Biopharma Co. Ltd. and West China Medical Center at Sichuan University.

Dihydroorotate dehydrogenase (DHODH) is an enzyme ubiquitously expressed in all tissues whose inhibition has proven effective in preventing viral replication. Previous knowledge on DHODH inhibitor vidofludimus calcium demonstrated that this compound inhibits viral replication of DNA, RNA and retroviruses and induces innate immune responses that lead to an antiviral state thus inhibiting virus reactivation.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aravive, Astellas, Bayer, Bioartic, Bionxt, Biophytis, Cabaletta, Cormedix, Eisai, Kamada, Kimera, Orchard, Phio, Sarepta, Virios, YS.

Kimera Labs Inc. has received IND approval from the FDA to study the company’s exosomes in a phase I/IIa trial, which is set to begin next month.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ani, ARS, Bloomsbury Genetic Therapies, Byondis, Clearmind, Decibel, Hefei Tianhui, Immpact, Innovent, Lianbio, Novavax, Nuvectis, Oramend, Pyxis, Regeneron, Sisaf.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations:  AB, Astrazeneca, Biophytis, Chiesi, Eli Lilly, Hemogenyx, Lighthouse, Minerva, Protalix, Servier, Theravance.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alx, Anokion, Aurinia, Boehringer Ingelheim, Boundless, Can-Fite, Celcuity, Cybin, Delix, Eli Lilly, Enanta, Ensysce, Gilead, Hookipa, Janssen, Lassen, Longeveron, Novavax, NS, Palatin, Seres, Summit, Trefoil.